Summit is committed to improving patients’ quality of life, extending their potential lifespan, and addressing serious unmet medical needs. Our goal is to provide access to our medicines at the appropriate time and in the manner that is most beneficial to the relevant patient populations. We believe that participation in our ongoing clinical trials is the safest and most effective way to achieve this goal, and we encourage patients to discuss these options with their physicians. 

Currently, our investigational medicine, ivonescimab, is being studied to demonstrate its efficacy and establish its safety profile in patients across North America,  Europe as well as Japan. Until ivonescimab’s efficacy and safety are demonstrated, Summit will not be making it available through expanded access. We strongly encourage participation in a clinical trial as the best way to access our investigational therapies. More information about our ongoing clinical trials can be found on the ClinicalTrials.gov website. 

In accordance with the 21st Century Cures Act, Summit reserves the right to revise this policy at any time. 

For additional information please contact medinfo@smmttx.com.